

EN

Back



BEAM Stock Rises 59% on Promising Sickle Cell Drug Data

Stock NewsThemesBEAM Stock Rises 59% on Promising Sickle Cell Drug Data

BEAM Stock Rises 59% on Promising Sickle Cell Drug Data

Edgen Stock·Jan 02 2026, 20:30

Share to

Share to

Copy link

source:

[1] Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry? (https://finance.yahoo.com/news/beams-gene-edi ...)

Related News

Analysts Project Strong 2026 Earnings to Boost Stocks

Jan 03 2026, 20:07

Analysts Project Strong 2026 Earnings to Boost Stocks

Analysts forecast that robust corporate earnings in 2026 will support US equity markets, but the Federal Reserve's uncertain policy path tempers the near-term outlook.

Fluor Sets February 17 Date for Q4 2025 Earnings Release

Jan 03 2026, 19:58

Fluor Sets February 17 Date for Q4 2025 Earnings Release

Fluor Corporation will report its fourth-quarter 2025 financial results on February 17, 2026, ahead of an investor conference call.

Ukraine and US to Finalize Security Pact in January 6 Paris Talks

Jan 03 2026, 19:13

Ukraine and US to Finalize Security Pact in January 6 Paris Talks

Ukrainian President Zelensky announced he will meet a U.S. team in Paris on January 6th to finalize a security guarantee agreement for Ukraine.